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Abstract: Besides being important in the fermentation of foods and beverages, yeasts have 
shown numerous beneficial effects on human health. Among these, probiotic effects are the 
most well known health effects including prevention and treatment of intestinal diseases 
and immunomodulatory effects. Other beneficial functions of yeasts are improvement of 
bioavailability of minerals through the hydrolysis of phytate, folate biofortification and 
detoxification of mycotoxins due to surface binding to the yeast cell wall.  
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1. Introduction 
Fermentation is one of the oldest forms of food processing and preservation in the world. Since very 
early times, humans have been exploiting yeasts and their metabolic products, mainly for baking and 
brewing. Nowadays, the products of modern yeast biotechnology form the backbone of many 
commercially important sectors, including foods, beverages, pharmaceuticals, industrial enzymes and 
others. Saccharomyces cerevisiae, which according to EFSA (The European Food Safety Authority) 
has a QPS (Qualified Presumption of Safety) status [1], is the most common yeast used in food 
fermentation where it has shown various technological properties. Yeasts do also play a significant 
role in the spontaneous fermentation of many indigenous food products. A review on S. cerevisiae in 
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African fermented foods has been provided by Jespersen [2]. Several beneficial effects on human 
health and well-being have been reported and there seems to be a need to understand the positive 
effects of yeasts, their mechanisms and employment of them. The present article reviews the major 
beneficial effects of yeasts, i.e., probiotic effects, biodegradation of phytate, folate biofortification and 
detoxification of mycotoxins, which has been summarized in Table 1. However, there are other 
reported effects such as enrichment of foods with prebiotics as fructooligosaccharides [3], lowering of 
serum cholesterol [4,5], antioxidative properties, antimutagenic and antitumor activities [6] etc. These 
topics will meanwhile not be the focus of the present review. Additional information on health 
significance and food safety of yeasts in foods and beverages can be obtained from Fleet and Balia [7]. 
Table 1. Overview of the major beneficial effects of yeasts. 
Activity  Yeast species   Heath effects  Ref. 
Probiotic effect  •  Saccharomyces cerevisiae var. 
boulardii 
Effect on enteric bacterial pathogen 
Maintenance of epithelial barrier 
integrity 
Anti-inflammatory effects 
 
Effects on immune response 
Trophic effects on intestinal mucosa 
Clinical effects on diarrheal diseases  
[16-35] 
[21,22,31,36] 
 
[21,22,31-35,37, 
39-41] 
[42-45] 
[46-49,52-53] 
[62-63,65-75] 
Biodegradation of 
phytate 
•  Saccharomyces cerevisiae, 
Saccharomyces kluyveri, 
Schwanniomyces castellii, 
Debaryomyces castellii, Arxula 
adeninivorans, Pichia anomala, 
Pichia rhodanensis, Pichia 
spartinae, Cryptococcus laurentii, 
Rhodotorula gracilis, Torulaspora 
delbrueckii, Kluyveromyces lactis 
Candida krusei (Issatchenkia 
orientalis) and Candida spp. 
Nutritional importance, i.e., 
bioavailability of divalent minerals 
such as iron, zink, calcium and 
magnesium 
[87-108] 
Folate 
biofortification 
•  S. cerevisiae 
•  Saccharomyces bayanus, 
Saccharomyces paradoxus, 
Saccharomyces pastorianus, 
Metschnikowia lochheadii, 
Debaryomyces melissophilus, 
Debaryomyces vanrijiae var. 
vanrijiae, Debaryomyces hansenii, 
Pichia philogaea, Kodamaea 
anthophila, Wickerhamiella 
lipophilia, Candida cleridarum 
and Candida drosophilae 
•  Candida milleri and T. delbrueckii  
•  Saccharomyces exiguous and 
Candida lambica  
•  P. anomala  and Candida glabrata 
•  Kluyveromyces marxianus and C. 
krusei (I. orientalis) 
Prevention of neural tube defects in 
the foetus, megaloblastic anaemia and 
reduction of the risk for 
cardiovascular disease, cancer and 
Alzheimer's disease  
[119-126,130] 
[121] 
 
 
 
 
 
 
 
 
[126] 
[128-129] 
 
[130] 
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Table 1. Cont. 
Degradation of 
mycotoxins 
•  S. cerevisiae  
•  Phaffia rhodozyma and 
Xanthophyllomyces dendrorhous 
Antitoxic in some degree  [138-141] 
[142] 
Absorption of 
mycotoxins  
•  S. cerevisiae  Antitoxic [143-155] 
2. Beneficial Effects of Yeast as Probiotics 
2.1. Taxonomic Characterization of Probiotic Yeasts 
Probiotics are defined as ‘live microorganisms which when administered in adequate amounts 
confer a health benefit on the host’ [8]. Probiotics may be consumed either as food components or as 
non-food preparations. There is a great interest in finding yeast strains with probiotic potential. 
Different yeast species such as Debaryomyces hansenii, Torulaspora delbrueckii [9], Kluyveromyces 
lactis, Kluyveromyces marxianus, Kluyveromyces lodderae [10] have shown tolerance to passage 
through the gastrointestinal tract or inhibition of enteropathogens. However, Saccharomyces boulardii 
is the only yeast with clinical effects and the only yeast preparation with proven probiotic efficiency in 
double-blind studies [11]. S. boulardii, isolated from litchi fruit in Indochina by Henri Boulard in the 
1920s, is commonly used as a probiotic yeast especially in the pharmaceutical industry and in a 
lyophilized form for prevention and treatment of diarrhoea. In a study conducted by van der Aa Kühle 
and Jespersen [12] on commercial strains of S. boulardii, it was found that the S. boulardii strains 
morphologically and physiologically could be characterized as S. cerevisiae. Sequences of the D1/D2 
domain of the 26S rRNA gene were identical for all isolates examined and had 100 % similarity with 
the sequences of the type strain of S. cerevisiae (CBS 1171
T) and the sequenced S. cerevisiae strain 
S288c. All S. boulardii isolates were found to have the same ITS1-5.8S rRNA-ITS2 sequence, which 
displayed a close resemblance with the sequences published for S288c (99.9%), CBS 1171
T (99.3%) 
and other S. cerevisiae strains. Sequence analysis of the mitochondrial cytochrome-c oxidase II gene 
(COX2) also resulted in identical sequences for the S. boulardii strains and comparisons with available 
nucleotide sequences revealed close relatedness to strains of S. cerevisiae including S288c (99.5%) 
and CBS 1171
T (96.6%). The electrophoretic karyotypes of the S. boulardii strains appeared quite 
uniform and although very typical of S. cerevisiae, they formed a cluster separate from other strains 
within this species. The results of the study strongly indicated a close relatedness of S. boulardii to S. 
cerevisiae and thereby support the recognition of S. boulardii as a member of S. cerevisiae and not as a 
separate species. The fact that strains of S. boulardii should be seen as a separate cluster within the S. 
cerevisiae species is further supported by the fact that strains of S. boulardii previously have been 
reported to differ from strains of S. cerevisiae due to a specific microsatellite allele [13] as well as 
trisomy of the chromosome IX and altered copy numbers of specific genes [14]. Others have reported 
S. boulardii strains to tolerate acidic stress better and grow faster at 37 °C than S. cerevisiae [15]. Due 
to the fact that S. boulardii from a taxonomic point of view should not be recognized as a separate 
species, S. boulardii will in the following be referred to as S. cerevisiae var. boulardii. It is worth to 
notice that contrary to e.g., probiotic strains of lactic acid bacteria, apparently there seems not to be 
different strains within S. cerevisiae var. boulardii. Based on the similarity in different molecular Nutrients 2010, 2                              
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analyses, all isolates appear to originate from the one isolated from litchi fruit in Indochina by Henri 
Boulard [12].   
2.2. Experimental Effects of S. cerevisiae var. boulardii 
2.2.1. Effects on enteric bacterial pathogens 
Several studies have shown that S. cerevisiae var. boulardii confer beneficial effects against various 
enteric pathogens, involving different mechanisms as: (i) prevention of bacterial adherence and 
translocation in the intestinal epithelial cells, (ii) production of factors that neutralize bacterial toxins 
and (iii) modulation of the host cell signalling pathway associated with pro-inflammatory response 
during bacterial infection. 
Prevention of bacterial adherence and translocation in the intestinal epithelial cells is due to the fact 
that the cell wall of S. cerevisiae var. boulardii has the ability to bind enteropathogens. S. cerevisiae 
var.  boulardii cell wall has shown binding capacity to enterohaemorrhagic Escherichia coli and 
Salmonella enterica serovar Typhimurium [16]. Additionally, the yeast inhibits adherence of 
Clostridium difficile to Vero cells (derived from kidney epithelial cells). Pre-treatment of C. difficile or 
the Vero cells with S. cerevisiae var.  boulardii or its cell wall particles results in lowering the 
adherence of bacteria to the Vero cells. Yeast cells or cell wall particles are able to modify the surface 
receptors involved in adhesion of C. difficile through a proteolytic activity and by steric   
hindrance [17]. Administration of S. cerevisiae var. boulardii reduces adherence of enterotoxigenic E. 
coli to mesenteric lymph node in pigs intestine [18]. S. cerevisiae var. boulardii has also beneficial 
effect on Citrobacter rodentium-induced colitis in mice, which is due to attenuating the adherence of 
C. rodentium to host epithelial cells, through reduction in EspB and Tir protein secretions, respectively 
a translocator and an effector protein implicated in the type III secretion system (TTSS) [19]. In a study 
on rats, ingestion of S. cerevisiae var. boulardii decreased the incidence of antibiotic-induced bacterial 
translocation. The total bacteria count of fecal flora and especially the number of Gram-negative 
bacteria were significantly lower after intake of the yeast in addition to antibiotic [20]. However, in 
other studies on enteropathogenic E. coli-  or  Shigella-infected T84 cells (human colonic 
adenocarcinoma cell line) and on mice infected with S. enterica serovar Typhimurium or Shigella 
flexneri, in which S. cerevisiae var. boulardii demonstrated beneficial effects, no effect on modifying 
the bacterial adherence was observed [21-23]. 
S. cerevisiae var.  boulardii produces two proteins of 54 and 120 kDa being responsible for 
degradation or neutralisation of bacterial toxins. The 54 kDa protein is a serine protease that decrease 
the enterotoxic and cytotoxic activities of C. difficile by proteolysis of the toxin A and inhibition of 
binding of the toxin to its brush border membrane receptor. In vivo studies have shown that oral 
administration of S. cerevisiae var. boulardii or its supernatant decreases toxin A-induced intestinal 
secretion and permeability due to activity of this enzyme [24-26]. The 120 kDa protein has a non-
proteolytic activity, competes specifically with the chloride secretion stimulated by the toxins of 
Vibrio cholera by reducing the cyclic adenosine monophosphate (cAMP) in the intestinal cells [27,28]. 
Both S. cerevisiae var. boulardii and S. cerevisiae W303 have the ability to protect Fisher rats against 
cholera toxin [29]. S. cerevisiae var.  boulardii also synthesizes a protein phosphatase that Nutrients 2010, 2                              
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dephosphorylates endotoxins such as lipopolysaccharide of E. coli 055B5 and inactivates its cytotoxic 
effects [30]. 
In vitro studies using mammalian cell cultures have shown that S. cerevisiae var. boulardii modifies 
host cell signalling pathways associated with pro-inflammatory response during bacterial infection. 
The mechanism is based on blocking activation of nuclear factor-kappa B (NF-κB) and mitogen-
activated protein kinase (MAPK) which decreases the expression of inflammation-associated 
cytokines such as interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-α) and interferon gamma 
(IFN-γ) [22,31,32]. The exposure of mammalian cells to S. cerevisiae var. boulardii before addition of 
enteropathogenic and enterohaemorrhagic E. coli reduces activation of NF-κB and MAPK, diminish 
production of TNF-α and secretion of IL-8 [21,31], delay enterohaemorrhagic E. coli -induced 
apoptosis (due to the reduction of TNF-α) and decline pro-inflammatory cytokine synthesis [32]. S. 
cerevisiae var. boulardii  produces a 10 kDa protein that exerts anti-inflammatory effects after 
stimulation with C. difficile-toxin A due to decrease in secretion of IL-8 in human colonocytes and 
activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in both human 
colonocytes and murine ileal loops [33]. Sougioultzis et al. [34] has shown that S. cerevisiae var. 
boulardii produces a low molecular weight soluble factor (< 1 kDa) which blocks NF-κB activation 
and NF-κB-mediated IL-8 gene expression in intestinal epithelial cells and monocytes. Expression of 
the pro-inflammatory cytokine IL-1α also decreased in IPEC-J2 cells (porcine intestinal epithelial cell 
lines) exposed to enterohaemorrhagic E. coli, when cells were pre- and co-incubated with S. cerevisiae 
var. boulardii [35]. 
2.2.2 Maintenance of epithelial barrier integrity 
Klingberg et al. [36] have shown that exposure of different strains of S. cerevisiae var. boulardii 
and S. cerevisiae to Caco-2 cells (human epithelial colorectal adenocarcinoma cell lines) increased the 
transepithelial electrical resistance (TER) across polarized monolayers of cells. In another study, 
infection of T84 cells with enteropathogenic E. coli reduced the monolayer transepithelial resistance 
and distribution of tight-junction-associated protein Zonula occludens (ZO-1) was altered, which 
caused disruption of epithelial barrier structure [21]. Presence of S. cerevisiae var. boulardii in the 
infection showed no alteration in the transepithelial resistance and ZO-1 protein distribution, 
suggesting a protective effect of S. cerevisiae var. boulardii on the tight-junctions structure of T84-
infected cells. During bacterial infection, the myosin light chain protein (MLC) is phosphorilated and 
the tight-junctions are disrupted. Dahan et al. [31] have shown that S. cerevisiae var. boulardii 
abolished phosphorylation of MLC and thereby eliminated the reduction of TER after infection of cells 
with enterohaemorrhagic E. coli and in that way preserved the barrier function. In Shigella-infected 
T84 cells, the yeast positively affected tight-junctions proteins (claudin-1 and ZO-2) and significantly 
protected the barrier function [22]. Shigella-infected cellular monolayer had a dramatic decrease in 
claudin-1 and ZO-2 levels. In the presence of yeast, cellular monolayer exhibited larger amounts of 
these proteins. These results demonstrate that S. cerevisiae var. boulardii enhances the ability of 
intestinal epithelial cells to restore the tight-junction structure and the barrier permeability. 
 Nutrients 2010, 2                              
 
 
454
2.2.3. Anti-inflammatory effects 
Besides reducing inflammation during bacterial infection by interfering with the host cell signalling 
pathways, S. cerevisiae var. boulardii also stimulates the peroxisome proliferator-activated receptor-
gamma (PPAR-γ) expression in human colonocytes and reduces the response of human colon cells to 
pro-inflammatory cytokines [37]. PPAR-γ is a nuclear receptor expressed by several cell types 
including intestinal epithelial cells, dendritic cells, T and B cells, and can act as a regulator of the 
inflammation [38]. S. cerevisiae var. boulardii has been reported to modify the migratory behaviour of 
lymphocytes. This was observed in a mice model of inflammatory bowel disease (IBD), where 
inhibition of inflammation in the colon was detected in animals treated with S. cerevisiae var. 
boulardii. The inhibition was due to decrease in the production of IFN-γ and a modification of T cell 
distribution. There was a decrease in IFN-γ-producing CD4
+ T cells within the colonic mucosa and an 
increase in IFN-γ-producing T cells in the mesenteric lymph nodes. In addition, S. cerevisiae var. 
boulardii supernatant modifies the capacity of endothelial cells to adhere to leucocytes, allowing better 
cell rolling and adhesion [39]. In inflammatory bowel disease (IBD), production of high levels of nitric 
oxide (NO) and inducible nitric oxide synthase (iNOS) activity is associated with inflammatory effects 
[40]. The inhibitory effect of S. cerevisiae var. boulardii on iNOS activity has been investigated by 
Girard  et al. [41] in rats with castor oil-induced diarrhoea. Administration of yeast blocked the 
production of the citrulline (a marker of NO production). The iNOS inhibition by S. cerevisiae var. 
boulardii may be beneficial in the treatment of diarrhoea and/or IBD associated with overproduction  
of NO.  
2.2.4. Effects on immune response 
There are several studies indicating the stimulation of the host cell immunity, both innate and 
adaptive immunity, by S. cerevisiae var. boulardii in response to pathogen infections. Oral 
administration of S. cerevisiae var. boulardii in healthy volunteers revealed several cellular and 
humoral changes in peripheral blood. This contributes to the activation of the reticuloendothelial and 
complement system, demonstrating the stimulation of the innate immune system by the yeast [42]. 
Oral ingestion of S. cerevisiae var. boulardii stimulated secretion of immune factors, i.e., adaptive 
immunity. In a study by Buts et al. [43], the level of secretory immunoglobulin A (sIgA) increased 
57% in the duodenal fluid and the secretory component of immunoglobulins enhanced 69% in villus 
cells and 80% in crypt cells of rats treated with the high dose of yeast. Application of S. cerevisiae var. 
boulardii to mice treated with C. difficile toxin A caused a 1.8-fold increase in total sIgA levels and a 
4.4-fold increase in specific antitoxin A sIgA levels [44]. In another study, after intravenous 
administration of E. coli, germ-free mice mono-associated with S. cerevisiae var. boulardii showed 
higher clearance of the pathogen from the bloodstream compared to germ-free mice, which was 
correlated with earlier production of IFN-γ and IL-12 in the serum [45]. 
2.2.5. Trophic effects on intestinal mucosa 
Several studies have shown that S. cerevisiae var. boulardii exerts trophic effects restoring the 
intestinal homeostasis. Oral administration of yeast by human volunteers or rats enhanced the activity Nutrients 2010, 2                              
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of brush border membrane enzymes, e.g., sucrase-isomaltase, lactase, maltase-glucoamylase, α-
glucosidase and alkaline phosphatase, which have a positive influence on nutrient degradation and 
absorption [46,47]. Oral administration of yeast after partial resection of the small bowel, increased 
disaccharidase activities and improved the absorption of D-glucose as well as the expression of the 
sodium/glucose cotransporter-1 (SGLT-1) in the brush border of the remaining intestinal   
segments [48]. Improvement of expression of SGLT-1 by S. cerevisiae var. boulardii,  which is 
implicated in water and electrolyte re-absorption, could be beneficial in the treatment of diarrhoea and 
congenital sucrase-isomaltase deficiency. S. cerevisiae var. boulardii cells contain high level of 
polyamines and it has been suggested that endoluminal release of polyamines (mainly spermine and 
spermidin) by S. cerevisiae var. boulardii, may contribute to rise in expression of intestinal enzymes, 
i.e., increase in sucrase and maltase activity [49].  
Modification of luminal short-chain fatty acids (SCFAs) concentration is another trophic effect of 
the yeast. SCFAs are among the most important metabolites produced by anaerobic bacteria in the 
colon and are involved in water and electrolyte absorption by the colonic mucosa [50]. Patients on 
long-term total enteral nutrition have a decrease in number of fecal anaerobic bacteria and in the level 
of fecal SCFAs [51]. Schneider et al. [52] have shown that administration of S. cerevisiae var. 
boulardii in these patients increased the level of total fecal SCFAs up to 9 days after termination of the 
treatment. However, yeast did not modify the fecal flora. This increase in fecal SCFAs concentration 
may explain the preventive effects of the yeast in enteral nutrition-induced diarrhoea.  
S. cerevisiae var. boulardii further has the ability to prevent reactions to food antigens. In neonates 
and young infants, the quality of endoluminal proteolysis is very important in the absorption of 
completely or incompletely degraded proteins and antigens by the mucosal barrier with increased 
permeability. This is one of the fundamental mechanisms involved in food protein intolerance. Buts et 
al. [53] have shown the endoluminal release of a leucine aminopeptidase by S. cerevisiae var. 
boulardii in rats and thereby enhancement of N-terminal hydrolysis of oligopeptides in both 
endoluminal fluid and intestinal mucosa. Thus, they proposed that this function of S. cerevisiae var. 
boulardii could be important in preventing reactions to food antigens when mucosal permeability  
is increased.  
2.3. Application of S. cerevisiae var. boulardii in Clinical Trails 
S. cerevisiae var. boulardii has been used in different clinical trails against different diarrhoeal 
diseases and has shown promising results. Treatment with S. cerevisiae var. boulardii is well tolerated, 
except for sporadic reports of fungemia, in immune-compromised patients or patients with severe 
general or intestinal diseases in most cases infected through an indwelling central venous   
catheter [54-56]. One of the benefits of using S. cerevisiae var. boulardii as a probiotic is the natural 
resistance of that to antibacterial antibiotics, thus it can be prescribed to patients receiving antibacterial 
antibiotic therapy.  
Antibiotic-associated diarrhoea (AAD) is a common complication of treatment with antibiotics 
caused by disruption of normal gut microbiota and colonization of pathogenic bacteria which results in 
an acute inflammation of the intestinal mucosa. The most common opportunistic pathogen related to 
AAD is C. difficile [57-59]. Among other infectious organisms Staphylococcus aureus, Clostridium Nutrients 2010, 2                              
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perfringens,  Klebsiella oxytoca,  Candida species, E. coli and Salmonella species can be   
mentioned [60,61]. S. cerevisiae var. boulardii has been comprehensively evaluated for the prevention 
of AAD and the potential effect of the yeast in decreasing the ADD in adults and children has been 
proven [62,63]. 
Traveller’s diarrhoea is a common health complaint among persons travelling from low risk regions 
to developing countries where enteric infection is hyper-endemic. Enterotoxigenic E. coli, Shigella and 
Salmonella account for about 80% of the cases with an identified pathogen [64]. In a meta-analysis 
study performed by McFarland [65], it has been concluded that S. cerevisiae var. boulardii has a 
significant efficacy on the prevention of Traveller’s diarrhoea. 
Several randomized placebo-controlled studies have proven the efficacy of S. cerevisiae var. 
boulardii in the treatment and prevention of acute infectious [66,67]. Intestinal disorder and diarrhoea 
are also common complications in critically ill patients with enteral nutrition which is caused by 
alteration in the colonic microbiota [51]. The effect of S. cerevisiae var. boulardii to prevent and 
reduce the incidence of diarrhoea and to decrease the length of this disease has been demostrated [68]. 
In the patient with AIDS-associated diarrhoea, the efficacy of S. cerevisiae var. boulardii has been 
proven by a randomized, double-blind trail [69,70]. 
S. cerevisiae var. boulardii has also shown positive results in patients with irritable bowel syndrome 
(IBS). In a double-blind, placebo-controlled study, performed on patients with diarrhoea-predominant 
IBS, administration of S. cerevisiae var. boulardii decreased the daily number of stools and improved 
the consistency of the stools [71]. A double-blind study on the patients with Crohn's disease with 
moderate activity showed that the addition of S. cerevisiae var. boulardii to conventional therapy 
considerably reduced bowel movements [72]. In patients with Crohn's disease of the ileum or colon 
who had been in remission for more than 3 months, treatment with S. cerevisiae var. boulardii together 
with the conventional therapy was more efficient in preventing relapse, compared to conventional 
therapy alone [73]. In patients with mild-to-moderate ulcerative colitis, addition of yeast to the 
conventional therapy resulted in clinical remission for 68% of patients [74]. In a randomized-placebo 
study on the patients with Crohn’s disease in remission, addition of S. cerevisiae var. boulardii to the 
baseline medications improved intestinal permeability with a decrease in the lactulose/mannitol   
ratio [75]. 
3. Beneficial Effects of Yeasts on Bioavailability of Nutrients 
3.1. Biodegradation of Phytate by Yeasts 
3.1.1. Antinutritional effects of phytate 
Phytic acid or phytate (myo-inositol hexakisphosphate, IP6) is the primary storage form of 
phosphorus in mature seeds of plants and it is particularly abundant in many cereal grains, oilseeds, 
legumes, flours and brans. Phytate has a strong chelating capacity and forms insoluble complexes with 
divalent minerals of nutritional importance such as iron, zink, calcium and magnesium [76-78]. Human 
as well as monogastric animals like poultry and pigs, lack the required enzymes in the gastrointestinal 
tract for degradation and dephosphorylation of the phytate complex. Besides, lowering the 
bioavailability of divalent ions, phytate may have negative influence on the functional and nutritional Nutrients 2010, 2                              
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properties of proteins such as digesting enzymes [79]. In addition, lower inositol phosphates attained 
from degradation of phytate have a positive role in cancer prevention and treatment [80,81].  
Dephosphorylation of phytate is catalyzed by phytases (myo-inositol-hexakisphosphate  
6-phosphohydrolases). Characterized phytases are nonspecific phosphatase enzymes, which release 
free inorganic phosphate (Pi) and inositol phosphate esters with a lower number of phosphate groups. 
Organisms such as plants and microorganisms extensively produce phytase enzymes and make the 
minerals and phosphorus present in the phytates available through a stepwise phytate hydrolysis [82]. 
In food processing, degradation of phytate can be catalyzed either by endogenous enzymes, naturally 
present in cereals, or by microbial enzymes produced by e.g., yeasts or/and lactic acid bacteria 
naturally present in flour or added as starter cultures [83]. Accordingly, improved adsorption of iron, 
zinc, magnesium and phosphorus can be achieved by degradation of phytate during food   
processing [84,85] or by degradation of phytate in the intestine [86].  
3.1.2. Phytase activity by yeasts 
Phytases are widespread in various microorganisms including filamentous fungi, Gram-positive and 
Gram-negative bacteria and yeasts [87]. Among yeasts, Candida krusei (Issatchenkia orientalis) [88], 
Schwanniomyces castellii [89],  Debaryomyces castellii [90], Arxula adeninivorans [91,92],  Pichia 
anomala [92,93], Pichia rhodanensis, Pichia spartinae [94], Cryptococcus laurentii [95], Rhodotorula 
gracilis [96], S. cerevisiae [97-100], Saccharomyces kluyveri, Torulaspora delbrueckii, Candida spp. 
and  Kluyveromyces lactis [94] have been identified as phytase producers. In a study by   
Olstorpe et al. [92] on the ability of different yeast strains (122 strains from 61 species) to utilize 
phytic acid as sole phosphorus source, strains of A. adeninivorans and P. anomala showed the highest 
volumetric phytase activities. 
Production of phytase by S. cerevisiae has been investigated in different studies [83,99]. The 
phytase activity of S. cerevisiae is partly due to the activity of the secretory acid phosphatases (SAPs), 
which are secreted by the cells to the growth media and are repressed by inorganic phosphate (Pi) [99]. 
However, the phytase activity of yeasts, e.g., during bread leavening, is relatively low [83,101,102]. 
This could be due to the repression of the SAPs by Pi [99]. Besides, repression of phytate-degrading 
enzymes is dependent on the pH and the medium composition. Andlid et al. [99] have shown that 
repression of phytate-degrading enzymes is weak in complex medium with pH 6.0 and high amount of 
phosphate. Regardless of Pi addition, the capacity to degrade phytase is highest at the pH far from the 
optimum pH for the SAPs, suggesting that pH has more effect on the expression of the enzyme that on 
the enzyme activity. 
S. cerevisiae as a phytase carrier in the gastrointestinal tract and hydrolysis of phytate after 
digestion has also been investigated. In a study using a high-phytase producing recombinant yeast 
strain at simulated digestive conditions, a strong reduction of phytate (up to 60%) in the early gastric 
phase was observed as compared to no degradation by wild-type strains. The phytase activity during 
digestion was influenced by the type of yeast strain, cell density, and phytate concentration. However, 
degradation in the late gastric and early intestinal phases was insignificant, in spite of high phytate 
solubility, high resistance against proteolysis by pepsin, and high cell survival [103]. This study also Nutrients 2010, 2                              
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showed the importance of pH as a limiting factor for phytase expression and/or activity, as observed 
by Andlid et al. [99]. 
3.1.3. Application of yeast phytases in foods 
Yeasts or yeast phytases can be applied for pre-treatment of foods to reduce the phytate contents or 
they can be utilized as food supplement in order to hydrolysis the phytate after digestion. The phytase 
activity of yeast during bread making for reduction of phytate content of bread have been examined. 
However, it seems to be too low to significantly influence the iron absorption [99]. Nevertheless, as 
explained earlier, during bread making, the content of phytic acid decreases. This is due to the action 
of phytases in the dough (cereal) and the activity of starter culture [83,104-106]. Chaoui et al. [106] 
have shown that phytase activity in sourdough bread is highest using combinations of yeasts and lactic 
acid bacteria as starter culture. The same result was found by Lopez et al. [105]. They found that 
phytate contents in yeast and sourdough bread were lower than in reconstituted whole-wheat flour and 
that mineral bioavailability could be improved by bread making especially using both yeast and lactic 
acid bacteria. Therefore a high-phytase S. cerevisiae strain, may be suitable for the production of food-
grade phytase and for direct use in food production [98]. Increasing the bioavailability of minerals is 
especially of importance in low-income countries. Therefore it is important to notice that apart from 
bread, reduction of phytates by yeast phytases have been observed in other plant-derived foods such as 
in ‘Icacina mannii paste’, a traditional food in Senegal, during fermentation with S. cerevisiae [107] 
and in ‘Tarhana’, a traditional Turkish fermented food, using baker's yeast as a phytase source [108].   
3.2. Folate Biofortification by Yeasts 
3.2.1. Importance of folate in the human diet  
Folates (vitamin B9) are essential cofactors in the biosynthesis of nucleotides and therefore crucial 
for cellular replication and growth [109,110]. Plants, yeast and some bacterial species contain the 
folate biosynthesis pathway and produce natural folates, but mammals lack the ability to synthesize 
folate and they are therefore dependent on sufficient intake from the diet [111]. During the last years, 
folates have drawn much attention due to the various beneficial health effects following an increased 
intake. The role of folate in the prevention of neural tube defects in the foetus has been   
established [112,113] and sufficient folate intake may reduce the risk of cardiovascular   
disease [112,114], cancer [112,115] and even Alzheimer's disease [116]. The recommended dietary 
intake (RDI) for the adult population is between 200–300 µg/day for males and between 170–300 
µg/day for females according to the FAO/WHO in the USA and several European countries [117]. 
Insufficient folate levels result in prolonged cell division, which leads to megaloblastic anaemia [118].  
3.2.2. Folate production by yeasts 
S. cerevisiae is a rich dietary source of native folate and produces high levels of folate per   
weight [119]. Besides the role as a biofortificant in fermented foods, high producing strains may be 
used as biocatalysts for biotechnological production of natural folates. The folate level can be 
considerably augmented in fermented foods using an appropriate yeast strain and by optimizing the Nutrients 2010, 2                              
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growth phase and cultivation conditions for the selected strain. Hjortmo et al. [120] have found that 
the growth medium and physiological state of cells are important factors in folate production. In 
synthetic growth medium, high growth rate subsequent to respiro-fermentative growth resulted in the 
highest specific folate content (folate per unit biomass). In complex media, the level of folate was 
much lower and less related to growth phase. The specific content of folate in yeast is not only species-
specific but also dependents on the yeast strain. In another study, Hjortmo et al. [121] investigated the 
folate content and composition and the dominating forms of folate found in 44 different strains of 
yeasts belonging to 13 different yeast species cultivated in a synthetic medium at standard conditions. 
There was a large diversity in relative amounts of folate content among the studied yeasts. 
Tetrahydrofolate (H4folate) and 5-methyl-tetrahydrofolate (5-CH3-H4folate) were the dominating 
forms, which were varying extensively in relative amounts between different strains. Several strains 
showed a 2-fold or higher folate content as compared to the control strain, i.e., a commercial strain of 
Baker's yeast. This indicates that by choosing an appropriate strain, the folate content in yeast-
fermented foods may be enhanced more than 2-fold. These scientists have shown that using a specific 
strain of S. cerevisiae cultured in defined medium and harvested in the respiro-fermentative phase of 
growth prior to dough preparation the folate content increased 3 to 5-fold (135–139 µg/100 g dry 
matter) in white wheat bread, compared to white wheat bread industrially processed with commercial 
S. cerevisiae (27–43 µg/100 g dry matter) [122].  
3.2.3. Effect of yeasts on folate biofortification of food  
Cereals, especially whole grain products, are the main supplier of folate in the diet. Yeast has 
crucial effects on the folate contents of breads. Breads prepared with baking powder have the lowest 
folate contents, while addition of yeast results in higher folate content in bread [123]. The variety of 
sourdoughs and baking processes obviously lead to great variation in folate content of breads. Total 
folate content increases considerably during sourdough fermentation due to the growth of   
yeasts [123,124]. However, there would be some losses (about 25%) in the amount of folate following 
the baking [123]. Final folate content is dependent on the microflora and amylolytic activity of flour, 
starter cultures and baking conditions [125]. Other microorganisms present in the sourdough like lactic 
acid bacteria may also influence the folate content. In a study, Kariluoto et al. [126] investigated the 
ability of typical sourdough yeasts (S. cerevisiae, Candida milleri, and T. delbrueckii) and lactic acid 
bacteria to produce or consume folates during sourdough fermentation. Yeasts increased the folate 
contents of sterilised rye flour-water mixtures to about 3-fold after 19 h, whereas lactobacilli not only 
did not produce folates but also decreased it to ultimately half amount. Although the lactobacilli 
consumed folates, their effect on folate contents in co-cultivations with yeasts was minimal. 
In beer, the amount of folate enhances due to synthesis by the yeast during the initial period of the 
fermentation. However, since yeast folate is intracellular, after cropping the yeast, folate will be 
eliminated from the beer and this is regardless the type of yeast. Some beer brands, which have a 
secondary fermentation step (often in the bottle), contain higher level of folate [125]. 
Production of folate in kefir has also been investigated. Kefir is a fermented milk beverage that 
originated in Eastern Europe and regarded as a natural probiotic product, i.e., a health promoting 
product [127]. It is produced by the fermentation of milk with kefir granules (grains) and contains Nutrients 2010, 2                              
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different vitamins and minerals. Kefir granules have a varying and complex microbial composition 
including species of lactic acid bacteria (as the largest portion of microorganism), acetic acid bacteria, 
yeasts and mycelial fungi. Yeasts isolated from Kefir grains include Kluyveromyces marxianus, 
Saccharomyces exiguus, Candida lambica and C. krusei (I. orientalis) [128]. Kefir contains high folate 
content, which is produced by the yeast and not the lactic acid bacteria [129]. In a study,   
Patring et al. [129] investigated the folate content of different yeast strains isolated from Russian kefir 
granules, belonging to different Saccharomyces and Candida species. Kefir yeast strains showed high 
folate-producing capacity. The most abundant folate forms were 5-CH3-H4folate (43–59%) and 5-
formyltetrahydrofolate (5-HCO-H4folate, 23–38%), whereas H4folate occurred in a minor proportion 
(19–23%). By choosing yeast strains that produce a higher proportion of the most stable folate forms 
such as 5-HCO-H4folate and 5-CH3-H4folate, it is possible to improve the stability of folates during 
fermentation and storage, and thus to increase the folate content in kefir products. 
Recently, the folate content of a traditionally fermented maize-based porridge, called togwa, 
consumed in rural areas in Tanzania has been investigated by Hjortmo et al. [130]. The yeasts strains 
belonged to C. krusei (I. orientalis), P. anomala, S. cerevisiae, K. marxianus and Candida glabrata. 
The major folate forms found during the fermentations were 5-CH3-H4folate and H4folate. The 
content of H4folate, per unit togwa, remained quite stable at a low level throughout the experiment for 
all strains, while the concentration of 5-CH3-H4folate was highly strain- and time-dependent. The 
highest folate concentration was found after 46 h of fermentation with C. glabrata, corresponding to a 
23-fold increase compared with unfermented togwa. As for degradation of phytate, selection of 
appropriate yeast strains as starter cultures in indigenous fermented foods appears to have high 
potential in especially developing countries where the vitamin intake generally is lower. Compared to 
e.g., lactic acid bacteria yeast are much more robust and may therefore more easily be distributed as 
starter cultures. 
4. Beneficial Effects of Yeasts on Detoxification of Mycotoxins 
4.1. Prevention of Toxic Effects of Mycotoxins 
Mycotoxins are secondary metabolites produced by fungi belonging mainly to the Aspergillus, 
Penicillium and Fusarium genera. Agricultural products, food and animal feeds can be contaminated 
by these toxins and lead to various diseases in humans and livestocks [131]. Contamination of 
agricultural products by mycotoxins is a worldwide dilemma, however it is rigorous in tropical and 
subtropical regions [132]. The most important mycotoxins are the aflatoxins, ochratoxins, fumonisins, 
deoxynivalenol (DON), zearalenone (ZEA) and trichothecenes [133,134]. There are three general 
strategies in order to prevent the toxic effects of mycotoxins in foods: (i) prevention of mycotoxin 
contamination (ii) decontamination/detoxification of foods contaminated with mycotoxins and (iii) 
inhibition of absorption of consumed mycotoxin in the gastrointestinal tract [135]. The ideal solution 
to reduce the health risk of mycotoxins is to prevent contamination of foods with them. Unfortunately, 
this can not be completely avoided and sporadically mycotoxin contamination is reported in food 
products, especially in the developing world [136]. Therefore, there is an increased focus on effective 
methods for detoxification of mycotoxins present in foods and also on the inhibition of mycotoxin 
absorption in the gastrointestinal tract. Various physical and chemical methods are available for the Nutrients 2010, 2                              
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detoxification of food products contaminated with mycotoxins. However, due to disadvantages of 
these methods, such as possible losses in the nutritional quality of treated commodities, limited 
efficacy, reduction of sensory quality and high cost of equipment, their application has been   
restricted [135]. An alternative strategy could be utilization of microorganisms capable of detoxifying 
mycotoxins in contaminated foods and feeds. 
4.2. Biodegradation of Mycotoxins by Yeasts 
Interests in biodegradation of mycotoxins have been increased significantly, since it is specific and 
environmentally friendly to reduce or eliminate the possible contaminations of mycotoxins in foods. 
Various microorganisms such as soil or water bacteria, fungi, and protozoa as well as specific enzymes 
isolated from microbial systems are able to some extent and with varied efficiency to degrade 
mycotoxins to less- or non-toxic products [137]. Degradation of mycotoxins subsequent to yeast 
fermentation has been reported in different studies. Degradation of patulin during fermentation of 
apple juice by S. cerevisiae with E-ascladiol and Z-ascladiol as major metabolites [138] and 
degredation of zearalenone by several yeast strains has been observed [139]. However, degradation of 
zearalenone leads to conversion of that to α- and β-zearalenol, which are still toxic. Degradation of 
ochratoxin A, fumonisins B1 and B2 [140], deoxynivalenol and T-2 toxin [141] by S. cerevisiae has 
been reported. Two yeast strains, Phaffia rhodozyma and Xanthophyllomyces dendrorhous, have also 
been shown to have ochratoxin A (OTA) degrading activity by converting OTA to ochratoxin α 
possibly mediated by an enzyme related to carboxypeptidases [142].  
4.3. Mycotoxin Absorption by Yeasts 
Inhibition of mycotoxin absorption in the gastrointestinal tract is another way to prevent the toxic 
effects of mycotoxins. There has been increased interest in the use of mycotoxin binding agents, e.g., 
yeasts and yeast-derived products, which can be added to the diet to bind mycotoxins. S. cerevisiae has 
the ability to bind mycotoxins as reviewed by Shetty and Jespersen [143]. The mechanism of 
detoxification by yeast is due to the adhesion of mycotoxins to cell-wall components. As for binding of 
pathogenic bacteria [16], mannan components of the cell wall play a major role in mycotoxin   
binding [144]. In vitro efficacy of esterified glucomannan to bind aflatoxin B1, ochratoxin A and T-2 
toxin, when present alone or in combination, was assessed in toxin-contaminated feed. Esterified 
glucomannan showed significantly higher binding ability to aflatoxin B1 than to ochratoxin A and T-2 
toxin in a dose dependent manner [145]. In a study by Aravind et al. [146] performed on broiler chicks 
to determine the efficacy of esterified glucomannan in counteracting the toxic effects of mycotoxins in 
naturally contaminated diet (aflatoxin, ochratoxin, zearalenone and T-2 toxin), it was observed that 
esterified glucomannan effectively improved the growth depression caused by mycotoxins. Strains of 
S. cerevisiae have been shown to bind ochratoxin A [147] and zearalenone as well [148]. Ochratoxin A 
and T-2 toxins also bind to glucomannan component of cell wall [145,149]. However, zearalenone 
bind to β-d-glucans of yeast cell wall [148]. It has been shown that yeast cell wall derived products 
efficiently adsorbed zearalenone (>70%) in an in vitro model that resembled the different pH 
conditions in the pig gastrointestinal tract, but they were not able to bind deoxynivalenol in a 
considerable percentage [150]. In study on mice, when dried yeast and yeast cell walls were added to Nutrients 2010, 2                              
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the diet along with aflatoxin B1, a significant reduction in the toxicity was observed [151]. Similarly, 
Madrigal-Santillán et al. [152] described the potential of S. cerevisiae to improve weight gain and 
reduce genotoxicity of aflatoxin B1 in mice fed with contaminated corn.  
Even though several trials have been made for decontamination of animal feeds by yeast, very little 
have so far been conducted on decontamination of foods and beverages. Binding of mycotoxins to 
yeast has especially been investigated during winemaking. It has been shown that yeasts can bind to 
ochratoxin A and remove it from the white and red wine. Ochratoxin A removal from grape must was 
due to binding of the toxin to the yeast cell wall, and mannoproteins were involved in the mycotoxin 
absorption during winemaking. The implication of this finding could be very important in the 
winemaking of must contaminated with ochratoxin A [153,154]. Oenological strains of Saccharomyces 
yeasts can also be used for the decontamination of ochratoxin A in synthetic and natural grape juice. 
Heat-treated cells showed higher absorption (90% w/w) compared to viable cells (35% w/w) showing 
the involvement of physical binding, and cell density played an important role in absorption efficiency. 
Dead yeasts do not pose any quality or safety problems and can be potentially used for detoxification 
of the grape juice [147]. S. cerevisiae is one of the most important microorganisms involved in food 
fermentations in tropical countries with high level of mycotoxin contamination in the foods. Shetty et 
al. [155] have investigated Aflatoxin B1 binding abilities of S. cerevisiae strains isolated from 
fermented maize dough (Kenkey) and sorghum beer (Pito), indigenous fermented foods from Ghana, 
West Africa. They showed that aflatoxin binding was strain specific and strains were found to bind 
10–40% and some of them more than 40% of the added aflatoxin B1 at standard condition. Highest 
binding capacity was observed at the exponential growth phase with 53% binding of the total toxin and 
the binding reduced towards the stationary phase. Aflatoxin B1 binding increased in a dose dependent 
manner after addition of aflatoxin, regardless to the temperatures ranging from 20 to 37 °C, but was 
significantly reduced at 15 °C. Heat and acid treated cells showed higher binding capacity, i.e., up to 
78% binding of the total added toxin [155]. Following this study unpublished results by Jespersen et 
al. have shown the yeast-aflatoxin B1 complex to be stable during the passage of an in vitro 
gastrointestinal tract model indicating that the aflatoxin will not be absorbed in the gastrointestinal 
tract but excreted together with the yeast cells in the human feces. Additionally, strains of S. cerevisiae 
isolated from indigenous fermented foods which are effective aflatoxin binders have been proven to be 
usable as starter cultures with additional capacities to decontaminate mycotoxins in fermented   
maize products.  
5. Conclusions 
Yeasts are used in preparation of human foods and beverages, where they besides having 
technological functions, confer different beneficial effects on human health and well-being. Among 
these, the most well known is the probiotic effect, which has been proven for S. cerevisiae var. 
boulardii. This is the only yeast produced and used as a pharmaceutical product offering numerous 
valuable effects such as prevention and treatment of intestinal diseases and immunomodulatory effects. 
Since S. cerevisiae var. boulardii is recognised as a member of the species S. cerevisiae, it is most 
likely that also other strains within S. cerevisiae might show probiotics properties. Even though to 
date, most efforts have been focused on analysing the probiotic effects of S. cerevisiae var. boulardii Nutrients 2010, 2                              
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isolates. Similarly, other yeast species might have probiotic effects and confer positive effects on 
human health. Therefore, it is recommended that additional attempts are placed on discovering the 
probiotic properties among other yeast species and strains.  
Besides the role as probiotics, yeasts have other beneficial functions such as dephosphorylation of 
phytate and folate biofortification of foods. By choosing appropriate yeast strains as starter cultures 
and using optimized food processing techniques, it is possible to improve the nutritional value of foods 
in general. In low-income areas such as the developing countries, application of yeast strains with high 
phytase and/or folate producing capacity in indigenous food fermentation will increase the 
bioavailability of minerals and folate content in the foods and will reduce the risk of different diseases 
such as neural tube defects and anaemia. Therefore, investigation of potential yeast strains isolated 
from indigenous native foods with high phytase activity and/or high folate content is encouraged. 
Contamination of agricultural products by mycotoxins causes severe threat to both livestock 
productivity and human health and brings huge worldwide economic losses each year. This is 
especially a rigorous problem in tropical and subtropical regions. For this reason, isolation and 
application of yeast strains with high mycotoxin binding capacity from indigenous fermented foods 
would be a valuable alternative for decontamination of mycotoxins in food. Strains of yeast, e.g., S. 
cerevisiae with high mycotoxin binding abilities can be used as part of the starter cultures in the 
fermentation of food and beverages, and heat treated cell walls or purified components can be applied 
as additives in small quantities without compromising the characteristics of the final product. The 
application of S. cerevisiae as mycotoxin binders in human foods highly depends on stability of the 
yeast-mycotoxin complex through the passage of the gastrointestinal tract. Additional research efforts 
are required in this area to explore the great potential of using S. cerevisiae as a detoxifying agent in 
contaminated foods. 
So far, tremendous efforts have been placed on utilising the probiotic effects of especially lactic 
acid bacteria, whereas rather limited emphasis has been placed on the beneficial effects offered by 
yeast. Yeasts do meanwhile offer several advantages compared to lactic acid bacteria. They do have a 
more diverse enzymatic profile, they appear to have a more versatile effect on the immune system, 
they do provide protection against pathogenic bacteria and toxic compounds by surface binding and 
appear to be better suited for nutritional enrichment and delivery of bio-active molecules. Besides 
yeast are much more robust than lactic acid bacteria which make them easier to produce and to 
distribute, especially in less developed areas. It is therefore encouraged that additional efforts are 
placed on exploring the health beneficial effects of yeasts, especially those properties that can not be 
replaced by lactic acid bacteria. 
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